Skip to Main Content

Author Details

Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
1986
127
41
PMIDPaper TitleJournal TitlePublished Year
36263840Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.Haematologica2023
36263840Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.Haematologica2023
34801727Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.Mol Ther2022
35580141Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.Cancer Immunol Res2022
35726868Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.Pediatr Blood Cancer2022
34801727Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.Mol Ther2022
35180323Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.Am J Hematol2022
35112552Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).Haematologica2022
35580141Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.Cancer Immunol Res2022
35726868Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.Pediatr Blood Cancer2022
35180323Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.Am J Hematol2022
35112552Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).Haematologica2022
32959985Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction.Pediatr Blood Cancer2021
33633361Immunogenicity of CAR T cells in cancer therapy.Nat Rev Clin Oncol2021
33206937A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.Blood2021
32959985Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction.Pediatr Blood Cancer2021
34889354Managing therapy-associated neurotoxicity in children with ALL.Hematology Am Soc Hematol Educ Program2021
33633361Immunogenicity of CAR T cells in cancer therapy.Nat Rev Clin Oncol2021
34889354Managing therapy-associated neurotoxicity in children with ALL.Hematology Am Soc Hematol Educ Program2021
33206937A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.Blood2021
32219444Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.Blood2020
31969338Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.Clin Cancer Res2020
32007196CAR T-cell product performance in haematological malignancies before and after marketing authorisation.Lancet Oncol2020
31944549Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.Pediatr Blood Cancer2020
32219444Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.Blood2020
31981407Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.Pediatr Blood Cancer2020
31969338Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.Clin Cancer Res2020
31981407Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.Pediatr Blood Cancer2020
32007196CAR T-cell product performance in haematological malignancies before and after marketing authorisation.Lancet Oncol2020
31944549Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.Pediatr Blood Cancer2020
30891164Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells.J Extracell Vesicles2019
30891164Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells.J Extracell Vesicles2019
29339403A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.Blood2018
28991243Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation.Bone Marrow Transplant2018
29883379Domain II of <i>Pseudomonas</i> Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.Toxins (Basel)2018
294321545-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.Proc Natl Acad Sci U S A2018
29339403A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.Blood2018
29068565The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2-Implications for fellowship training.Pediatr Blood Cancer2018
29068564The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1-Current state of the workforce.Pediatr Blood Cancer2018
29728694Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia &amp; lymphoma study.Leukemia2018
29797659Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.Pediatr Blood Cancer2018
29883379Domain II of <i>Pseudomonas</i> Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.Toxins (Basel)2018
29728694Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia &amp; lymphoma study.Leukemia2018
294321545-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.Proc Natl Acad Sci U S A2018
29797659Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.Pediatr Blood Cancer2018
28991243Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation.Bone Marrow Transplant2018
29068565The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2-Implications for fellowship training.Pediatr Blood Cancer2018
29068564The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1-Current state of the workforce.Pediatr Blood Cancer2018
28891959The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.Cancers (Basel)2017
28983018Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.Blood2017
  • 1 - 50 of 254

Recommended Authors

Sawa Ito
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 7
Kara L Davis
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 3
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 2
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Aarthi Shenoy
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 5
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 1
Geoffrey D E Cuvelier
University of Manitoba
Career Start Year 2005
Number of shared co-authors 2
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 3
Eneida R Nemecek
Oregon Health Sciences University
Career Start Year 2002
Number of shared co-authors 10
Scott C Borinstein
Vanderbilt University Medical Center
Career Start Year 1998
Number of shared co-authors 2
Scott C Howard
College of Nursing
Career Start Year 1997
Number of shared co-authors 5
Leslie Lehmann
Dana Farber Cancer Institute/Boston Children's Hospital
Career Start Year 1996
Number of shared co-authors 3
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 2
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 6
Meenakshi Devidas
St Jude Children's Research Hospital
Career Start Year 1993
Number of shared co-authors 14
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 3
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 1
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 3
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 5
Shifra Ash
Ruth Rappaport Children's Hospital
Career Start Year 1988
Number of shared co-authors 0
Robert H Collins
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 5
Clayton A Smith
University of Colorado, Aurora CO.
Career Start Year 1987
Number of shared co-authors 5
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 8
Denis-Claude Roy
Universite de Montreal
Career Start Year 1985
Number of shared co-authors 2
Richard T Maziarz
Oregon Health & Science University
Career Start Year 1983
Number of shared co-authors 6
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Career Start Year 1982
Number of shared co-authors 14
Dietger Niederwieser
University of Leipzig
Career Start Year 1982
Number of shared co-authors 4
Stefan Burdach
Technische Universitat Munchen
Career Start Year 1981
Number of shared co-authors 3
Kenneth B Miller
Tufts Medical Center
Career Start Year 1981
Number of shared co-authors 2
John F DiPersio
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 7

Collaborators

Maryalice Stetler-Stevenson
National Cancer Institute, National Institutes of Health
Co-authored papers 12
Robert J Kreitman
National Cancer Institute
Co-authored papers 8
Kristin Baird
National Cancer Institute, National Institutes of Health
Co-authored papers 7
Steven Z Pavletic
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 6
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Co-authored papers 6
David F Stroncek
Center for Cellular Engineering, NIH Clinical Center, National Institutes of Health
Co-authored papers 6
Stefania Pittaluga
National Cancer Institute, National Institutes of Health
Co-authored papers 5
Patrick Brown
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 5
Elaine S Jaffe
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 4
Van Huynh
Co-authored papers 4
David S Ziegler
Co-authored papers 4
Bill H Chang
Oregon Health and Science University
Co-authored papers 4
Chimene Kesserwan
National Institutes of Health
Co-authored papers 3
Ming-Hui Wei
Yantai Affiliated Hospital of Binzhou Medical University
Co-authored papers 3
David M Loeb
Children's Hospital at Montefiore.
Co-authored papers 3
Daniel H Fowler
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Koen van Besien
University Hospitals of Cleveland
Co-authored papers 3
Sebastien Morisot
Co-authored papers 2
Lee J Helman
Osteosarcoma Institute
Co-authored papers 2
Mark Raffeld
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Brigitte C Widemann
Co-authored papers 2
Kwaku Ohene-Frempong
Sickle Cell Foundation of Ghana
Co-authored papers 2
Jerald P Radich
Fred Hutchinson Cancer Center
Co-authored papers 2
Edward W Cowen
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Co-authored papers 2
Paul L Martin
Duke University Medical Center
Co-authored papers 2
Carl H June
University of Pennsylvania Department of Pathology & Laboratory Medicine
Co-authored papers 2
Joanne Kurtzberg
Marcus Center for Cellular Cures, Duke University School of Medicine
Co-authored papers 2
Matthew J Oberley
Co-authored papers 2
Robert C Shamberger
Boston Children's Hospital
Co-authored papers 2
Curt I Civin
Center for Stem Cell Biology & Regenerative Medicine and.
Co-authored papers 2
Release 1.2